PL3384915T3 - Karymycyna do leczenia zakażeń prątkiem gruźlicy - Google Patents

Karymycyna do leczenia zakażeń prątkiem gruźlicy

Info

Publication number
PL3384915T3
PL3384915T3 PL16880885T PL16880885T PL3384915T3 PL 3384915 T3 PL3384915 T3 PL 3384915T3 PL 16880885 T PL16880885 T PL 16880885T PL 16880885 T PL16880885 T PL 16880885T PL 3384915 T3 PL3384915 T3 PL 3384915T3
Authority
PL
Poland
Prior art keywords
carrimycin
treatment
mycobacterium tuberculosis
tuberculosis infections
infections
Prior art date
Application number
PL16880885T
Other languages
English (en)
Inventor
Yiguang Wang
Yang Jiang
Xiaofeng Zhao
Weiqing He
Original Assignee
Shenyang Fuyang Pharmaceutical Technology Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenyang Fuyang Pharmaceutical Technology Co., Ltd. filed Critical Shenyang Fuyang Pharmaceutical Technology Co., Ltd.
Publication of PL3384915T3 publication Critical patent/PL3384915T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL16880885T 2015-12-31 2016-12-05 Karymycyna do leczenia zakażeń prątkiem gruźlicy PL3384915T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201511030787.7A CN105497053B (zh) 2015-12-31 2015-12-31 可利霉素在抗结核分枝杆菌感染中的应用
EP16880885.5A EP3384915B1 (en) 2015-12-31 2016-12-05 Carrimycin for the treatment of mycobacterium tuberculosis infections
PCT/CN2016/108502 WO2017114095A1 (zh) 2015-12-31 2016-12-05 可利霉素在抗结核分枝杆菌感染中的应用

Publications (1)

Publication Number Publication Date
PL3384915T3 true PL3384915T3 (pl) 2020-09-07

Family

ID=55705614

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16880885T PL3384915T3 (pl) 2015-12-31 2016-12-05 Karymycyna do leczenia zakażeń prątkiem gruźlicy

Country Status (21)

Country Link
US (1) US11000708B2 (pl)
EP (1) EP3384915B1 (pl)
JP (1) JP6770584B2 (pl)
KR (1) KR102808775B1 (pl)
CN (1) CN105497053B (pl)
AU (1) AU2016382584B2 (pl)
BR (1) BR112018013327A2 (pl)
CA (1) CA3010020A1 (pl)
CL (1) CL2018001804A1 (pl)
CO (1) CO2018007133A2 (pl)
DK (1) DK3384915T3 (pl)
ES (1) ES2785644T3 (pl)
MX (1) MX381113B (pl)
MY (1) MY191800A (pl)
PE (1) PE20190210A1 (pl)
PH (1) PH12018501394A1 (pl)
PL (1) PL3384915T3 (pl)
RU (1) RU2733382C2 (pl)
UA (1) UA121159C2 (pl)
WO (1) WO2017114095A1 (pl)
ZA (1) ZA201804398B (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105497053B (zh) 2015-12-31 2018-02-13 沈阳福洋医药科技有限公司 可利霉素在抗结核分枝杆菌感染中的应用
RU2746047C1 (ru) * 2017-04-06 2021-04-06 Шенянг Фуянг Фармасьютекал Технолоджи Ко., Лтд. Применение карримицина и его фармацевтически приемлемой соли для производства медикаментов для лечения и/или профилактики опухоли
CN110384802B (zh) * 2018-04-17 2021-09-17 沈阳福洋医药科技有限公司 一种用于预防和/或治疗发热的药物、组合产品及其应用
CN110384710B (zh) * 2018-04-17 2023-01-10 沈阳福洋医药科技有限公司 一种用于预防和/或治疗疼痛的药物、组合产品及其应用
WO2021219112A1 (zh) * 2020-04-30 2021-11-04 沈阳福洋医药科技有限公司 异戊酰螺旋霉素类化合物或其组合物在制备治疗脓毒症疾病药物中的应用
CN113577086B (zh) * 2020-04-30 2023-05-02 沈阳福洋医药科技有限公司 异戊酰螺旋霉素类化合物或其组合物在制备治疗免疫失调的药物中的应用
TW202237116A (zh) * 2020-12-02 2022-10-01 日商塩野義製藥股份有限公司 以組合細胞色素bc1抑制劑與克拉黴素或阿奇黴素為特徵之用於治療分枝桿菌感染之藥物
CN119405677B (zh) * 2025-01-08 2025-05-06 深圳国家感染性疾病临床医学研究中心 一种泰乐菌素的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2126108B1 (pl) * 1971-02-25 1974-08-02 Rhone Poulenc Sa
US7098219B2 (en) * 2000-08-01 2006-08-29 Wockhart Limited Inhibitors of cellular efflux pumps of microbes
CN1237976C (zh) * 2003-12-23 2006-01-25 沈阳同联集团有限公司 必特螺旋霉素及其在抗感染性疾病中的应用
JP2008520686A (ja) * 2004-11-17 2008-06-19 スミスクライン・ビーチャム・コーポレイション 新規な抗菌化合物の使用
DE102005058345A1 (de) * 2005-12-06 2007-06-14 Kern, Andreas, Dr. med. Verwendung eines oral einzunehmenden Antibiotikums
WO2008122038A1 (en) * 2007-04-02 2008-10-09 President And Fellows Of Harvard College Regulating autophagy
CA2800019C (en) * 2010-05-25 2015-05-26 Shenyang Tonglian Group Co., Ltd. Levocarrimycin, pharmaceutical compositions, preparation methods and uses thereof
EP2578595B1 (en) * 2010-05-25 2017-04-19 Shenyang Fuyang Pharmaceutical Technology Co., Ltd. Crystalline levoisovalerylspiramycin i
JP6116206B2 (ja) * 2012-11-26 2017-04-19 クリニプロ株式会社 吸入用パウダーの製造方法
CN103142520B (zh) * 2013-03-15 2015-04-01 沈阳同联集团有限公司 一种可利霉素片及其制备方法
CN105497053B (zh) * 2015-12-31 2018-02-13 沈阳福洋医药科技有限公司 可利霉素在抗结核分枝杆菌感染中的应用

Also Published As

Publication number Publication date
JP6770584B2 (ja) 2020-10-14
WO2017114095A1 (zh) 2017-07-06
KR102808775B1 (ko) 2025-05-16
BR112018013327A2 (pt) 2018-12-04
RU2018125622A3 (pl) 2020-03-26
KR20180098624A (ko) 2018-09-04
CL2018001804A1 (es) 2018-09-28
PH12018501394A1 (en) 2019-02-27
DK3384915T3 (en) 2020-05-04
CN105497053A (zh) 2016-04-20
AU2016382584A1 (en) 2018-07-26
ES2785644T3 (es) 2020-10-07
JP2019501220A (ja) 2019-01-17
RU2733382C2 (ru) 2020-10-01
MY191800A (en) 2022-07-15
UA121159C2 (uk) 2020-04-10
MX381113B (es) 2025-03-12
AU2016382584B2 (en) 2022-01-06
CO2018007133A2 (es) 2018-07-19
EP3384915A1 (en) 2018-10-10
ZA201804398B (en) 2019-09-25
EP3384915B1 (en) 2020-02-19
RU2018125622A (ru) 2020-01-31
US11000708B2 (en) 2021-05-11
EP3384915A4 (en) 2018-12-19
US20190001160A1 (en) 2019-01-03
CA3010020A1 (en) 2017-07-06
PE20190210A1 (es) 2019-02-07
CN105497053B (zh) 2018-02-13

Similar Documents

Publication Publication Date Title
IL263972A (en) Dihydropyranopyrimidines for the treatment of viral infections
IL255270A0 (en) exoskeleton
SG11201702688UA (en) Methods of treating rsv infections
SG11201609652RA (en) Treatment of polybacterials infections
IL247155A0 (en) Rapamycin for the treatment of lymphangioleiomyomatosis
PL3384915T3 (pl) Karymycyna do leczenia zakażeń prątkiem gruźlicy
GB201608885D0 (en) Treatment
GB201502137D0 (en) Treatment
PT3538379T (pt) Sistema de anotações apagáveis por humidade
GB201522243D0 (en) Treatment
SMT201900353T1 (it) Trattamento della sclerosi multipla
ZA201700916B (en) Heterobicyclic compounds and their use for the treatment of tuberculosis
ZA201906047B (en) Compounds for treating tuberculosis
IL253617A0 (en) Snekribirock for the treatment of leprosy
IL258137A (en) HIV treatment measures
GB201519450D0 (en) Novel treatment
GB201508841D0 (en) Treatment
GB201620323D0 (en) Treatment Device
ZA201901948B (en) Heteroaryltrifluoroborate compounds for the treatment of mycobacterial infections
GB201503008D0 (en) Treatment
PL3307267T3 (pl) Leczenie stwardnienia rozsianego
IL249616A0 (en) Methods for treating inflammation
GB201617107D0 (en) Treatment
GB201610403D0 (en) Cooling system treatment
GB201612260D0 (en) Treatment